Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

NCT04323748 ·Status: RECRUITING ·Phase: PHASE1

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

NCT05338190 ·Status: RECRUITING ·Phase: PHASE3

A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

NCT02137681 ·Status: WITHDRAWN ·Phase: PHASE3

A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

NCT00475423 ·Status: COMPLETED ·Phase: PHASE2

Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy

NCT00225875 ·Status: TERMINATED ·Phase: PHASE2

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

NCT04518475 ·Status: RECRUITING ·Phase: PHASE4

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

NCT01554514 ·Status: COMPLETED ·Phase: PHASE2

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

NCT07234019 ·Status: RECRUITING ·Phase: PHASE2

Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

NCT03443570 ·Status: UNKNOWN ·Phase: PHASE3

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

NCT01506414 ·Status: COMPLETED ·Phase: PHASE3

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

NCT00251277 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

NCT07206823 ·Status: RECRUITING ·Phase: NA

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

NCT00005652 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04200456 ·Status: TERMINATED ·Phase: PHASE3

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

NCT01672151 ·Status: COMPLETED

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962 ·Status: RECRUITING ·Phase: PHASE3

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

NCT00937131 ·Status: COMPLETED ·Phase: PHASE2

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT01713738 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04224688 ·Status: TERMINATED ·Phase: PHASE3

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

NCT01317966 ·Status: WITHDRAWN

Rituximab in Auto-Immune Hemolytic Anemia

NCT01181154 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

NCT01618734 ·Status: COMPLETED

Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

NCT01107951 ·Status: COMPLETED ·Phase: PHASE2

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

NCT01525836 ·Status: COMPLETED ·Phase: PHASE3